Cargando…
Developing drugs targeting CX3CL1 to treat heart diseases via immune/inflammatory mediation: Targeting CX3CL1 to treat heart diseases
Autores principales: | Zou, Lin, Ma, Junhua, Hu, Guiying, Zhu, Hongling, Zhang, Lijuan, Li, Xiangqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577471/ https://www.ncbi.nlm.nih.gov/pubmed/37580951 http://dx.doi.org/10.3724/abbs.2023157 |
Ejemplares similares
-
CX3CL1/CX3CR1 in Alzheimer's Disease: A Target for Neuroprotection
por: Chen, Peiqing, et al.
Publicado: (2016) -
Fractalkine Signalling (CX(3)CL1/CX(3)CR1 Axis) as an Emerging Target in Coronary Artery Disease
por: Loh, Shu Xian, et al.
Publicado: (2023) -
Therapeutic intervention of inflammatory/immune diseases by inhibition of the fractalkine (CX3CL1)-CX3CR1 pathway
por: Imai, Toshio, et al.
Publicado: (2016) -
Regulation and function of CX3CR1 and its ligand CX3CL1 in kidney disease
por: von Vietinghoff, Sibylle, et al.
Publicado: (2021) -
Modulating neurotoxicity through CX3CL1/CX3CR1 signaling
por: Limatola, Cristina, et al.
Publicado: (2014)